By the Numbers

Henry Ford Cancer: At a glance

  • >1,250 dedicated cancer team members
  • 94% of patients mark the highest rating possible for “would recommend”
  • >10,000 new patients annually
  • 9% year-over-year growth in all case volume
  • 18 multidisciplinary tumor boards
  • 5 hospitals
  • 10 outpatient treatment centers


Dramatic growth in cancer screening programs continues to improve outcomes

Henry Ford Health’s team-based approach to cancer screening continues to make an impact in the communities we serve.

While expanding our reach, we were the first in Michigan to offer the groundbreaking Galleri® test. Research has shown this test, from GRAIL, can detect a cancer signal shared across more than 50 types of cancer through a single blood draw. Since we began offering the test commercially in mid-2022, we have performed over 1,800 tests, in addition to over 2,000 completed as part of the Pathfinder II study.

In addition, Henry Ford Health is collaborating with the American Medical Group Association Foundation to help increase colorectal cancer screening rates among our average-risk patients aged 45-75.

Other highlights from our cancer screening programs include:

  • 24% increase in lung screenings
  • 17% increase in cervical screenings
  • 13% increase in colon screenings
  • 8% increase in PSA screenings
  • 9% increase in mammograms


Deborah’s Story
“Colorectal cancer screening is one of the most preventive tools and it saved my life,” says Deborah, a Stage 2 colon cancer survivor.

Examples of federally funded clinical trials and research grants

Henry Ford Cancer has a rich history of clinical trials and translational research, which has driven many new innovations in patient care. Our Cancer Clinical and Translational Research Office (CCTRO) underscores this commitment to research, and builds on our heritage of groundbreaking discovery. Some of our recent studies and grants include:

NCI RO1 grants received in 2023

Houtan Noushmehr, Ph.D.
Department of Neurosurgery
Circulating Cell-Free DNA Methylation as an Accurate Tool for Detection and Clinical Follow-up of Glioma

Meser Ali, Ph.D.
Department of Neurosurgery
Targeted Drug Delivery System to Overcome
Blood-Brain Barrier and Therapeutic Resistance to Current Standard of Care in Glioblastoma

Jagadananda Ghosh, Ph.D.
Department of Urology
Neuroendocrine Differentiation Post Anti-Androgenic Therapy: Role of Tribbles 2

Qing-Sheng Mi, Ph.D. and Li Zhou, M.D.
Department of Dermatology
VPS72 Controls Treg Cell Stability and Adaptation to Tumor Microenvironment


Frank’s Story
“I think when you’re given such a diagnosis, you’re willing to do or try anything,” says Frank, a clinical trial participant and Stage 3B lung cancer survivor.

Other clinical trials and grants

Ian Lee, M.D.
Department of Neurosurgery
A Phase 2b Clinical Study With a Combination Immunotherapy in Newly Diagnosed Patients With Glioblastoma—NCI

Farzan Siddiqui, M.D., Ph.D.
Department of Radiation Oncology
Feasibility of Semi-Permanent Tattoo for Treatment Alignment in Radiation Therapy—Henry Ford Health

Branislava Janic, Ph.D.
Department of Radiation Oncology
siRNA-based Gold Nanoparticles as a Therapeutic Enhancer for Triple Negative Breast Cancer (TNBC) Radiotherapy—NCI

Kyungmin Ji, Ph.D.
Department of Neurology
Paracrine Pathways Causal in Growth and Invasion of Neurofibromas: Contributions of Cellular Microenvironment— Department of Defense

18 Tumor Boards
Our tumor boards include a variety of fellowship-trained physicians and specialists who discuss and agree on the best treatment plan for you.

Cookie Consent

We use cookies to improve your web experience. By using this site, you agree to our Terms of Use. Read our Internet Privacy Statement to learn what information we collect and how we use it.

Accept All Cookies